Active surveillance: A potential strategy for select patients with small renal masses

Future Oncology

Volumn 7, Issue 10, 2011, Pages 1133-1147

  Smaldone, Marc C ^a   Uzzo, Robert G ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

active surveillance; competing risks; metastases; natural history; observation; renal cell carcinoma; renal neoplasms

Indexed keywords

ARTIFICIAL PNEUMOTHORAX; CANCER PATIENT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SURVEILLANCE; HUMAN; KIDNEY CANCER; KIDNEY TUMOR; METASTASIS; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS BIOPSY; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT;

EID: 80054089880     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.97     Document Type: Review

References (94)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010 CA Cancer J. Clin. 60(5), 277-300 (2010).
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer n the United States. JAMA 281(17), 1628-1631 (1999). (Pubitemid 29211773)
3. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J. Natl Cancer Inst. 98(18), 1331-1334 (2006). (Pubitemid 44530728)
4. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 113(1), 78-83 (2008). (Pubitemid 351976389)
5. Cooperberg MR, Mallin K, Ritchey J, Villalta JD, Carroll PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004 J. Urol. 179(6),2131-2135 (2008).
6. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology 51(2), 203-205 (1998). (Pubitemid 28093168)
7. Kutikov A, Fossett LK, Ramchandani P et al. Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology 68(4), 737-740 (2006). (Pubitemid 44633357)
8. Crispen PL, Boorjian SA, Lohse CM et al. Outcomes following partial nephrectomy by tumor size. J. Urol. 180(5), 1912-1917 (2008).
9. Remzi M, Ozsoy M, Klingler HC et al. Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J. Urol. 176(3), 896-899 (2006). (Pubitemid 44142601)
10. Hollenbeck BK, Taub DA, Miller DC, Dunn RL, Wei JT. National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology 67(2), 254-259 (2006). (Pubitemid 43189837)
11. Huang WC, Levey AS, Serio AM et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol. 7(9), 735-740 (2006). (Pubitemid 44283660)
12. McKiernan J, Simmons R, Katz J, Russo P. Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 59(6), 816-820 (2002). (Pubitemid 34522166)
13. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351(13), 1296-305 (2004).
14. Huang WC, Elkin EB, Levey AS, Jang TL, Russo P. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors - is there a difference in mortality and cardiovascular outcomes? J. Urol. 181(1), 55-61, discussion 61-62 (2009).
15. Thompson RH, Boorjian SA, Lohse CM et al. Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J. Urol. 179(2), 468-471 (2008).
16. Gill IS, Kavoussi LR, Lane BR et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J. Urol. 178(1), 41-46 (2007). (Pubitemid 46898481)
17. Van Poppel H, Da Pozzo L, Albrecht W et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59(4), 543-552 (2011).
18. Simhan J, Smaldone MC, Tsai KJ et al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. Eur. Urol. 60(4), 724-730 (2011) (Epub ahead of print).
19. Lane BR, Gill IS. 7-year oncological outcomes after laparoscopic and open partial nephrectomy. J. Urol. 183(2), 473-479 (2010).
20. Scoll BJ, Uzzo RG, Chen DY et al. Robot-assisted partial nephrectomy: a large single-institutional experience. Urology 75(6), 1328-1334 (2010).
21. Campbell SC, Novick AC, Belldegrun A et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182(4), 1271-1279 (2009).
22. Kutikov A, Kunkle DA, Uzzo RG. Focal therapy for kidney cancer: a systematic review. Curr. Opin Urol. 19(2), 148-153 (2009).
23. Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma - a meta-analysis and review. J. Urol. 179(4), 1227-1233 (2008).
24. Kutikov A, Egleston BL, Wong YN, Uzzo RG. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 28(2), 311-317 (2010).
25. Welch HG, Black WC. Overdiagnosis in cancer. J. Natl Cancer Inst. 102(9), 605-613 (2010).
26. Dall'Era MA, Cooperberg MR, Chan JM et al. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 112(8), 1650-1659 (2008). (Pubitemid 351536825)
27. Wilt TJ, Brawer MK, Barry MJ et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp. Clin. Trials 30(1), 81-87 (2009).
28. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J. Urol. 170(6 Pt 1), 2217-2220 (2003). (Pubitemid 37413960)
29. Thompson RH, Kurta JM, Kaag M et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J. Urol. 181(5), 2033-2036 (2009).
30. Rothman J, Egleston B, Wong YN, Iffrig K, Lebovitch S, Uzzo RG. Histopathological characteristics of localized renal cell carcinoma correlate with tumor size: a SEER analysis. J. Urol. 181(1), 29-33 (2009).
31. Kunkle DA, Crispen PL, Li T, Uzzo RG. Tumor size predicts synchronous metastatic renal cell carcinoma: implications for surveillance of small renal masses. J. Urol. 177(5), 1692-1626 (2007).
32. Nguyen MM, Gill IS. Effect of renal cancer size on the prevalence of metastasis at diagnosis and mortality. J. Urol. 181(3), 1020-1027 (2009).
33. Thompson RH, Hill JR, Babayev Y et al. Metastatic renal cell carcinoma risk according to tumor size. J. Urol. 182(1), 41-45 (2009).
34. Duffey BG, Choyke PL, Glenn G et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J. Urol. 172(1), 63-65 (2004). (Pubitemid 41615039)
35. Lane BR, Abouassaly R, Gao T et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116(13), 3119-3126 (2010).
36. Arrontes DS, Acenero MJF, Gonzalez JIG, Munoz MM, Andres PP. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J. Urol. 179(3), 857-861 (2008).
37. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk anlysis. Cancer 109(9), 1763-1768 (2007). (Pubitemid 46668538)
38. Lughezzani G, Sun M, Budaus L, Thuret R, Perrotte P, Karakiewicz PI. Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J. Clin. Oncol. 28(18), E99-E300 (2010).
39. Kutikov A, Egleston BL, Smaldone MC, Canter D, Wong YN, Uzzo RG. Quantification of competing risks of death with localized renal cell carcinoma (RCC): a comprehensive nomogram incorporating co-morbidities Presented at: American Urologic Association Annual Meeting. Washington, DC, USA, 14-19 May 2011
40. Uzzo RG. Renal masses - to treat or not to treat? If that is the question are contemporary biomarkers the answer? J. Urol. 180(2), 433-434 (2008).
41. Jeldres C, Sun M, Liberman D et al. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J. Urol. 182(6), 2585-2589 (2009).
42. Lane BR, Babineau D, Kattan MW et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J. Urol. 178(2), 429-434 (2007). (Pubitemid 47030487)
43. Lane BR, Samplaski MK, Herts BR, Zhou M, Novick AC, Campbell SC. Renal mass biopsy - a renaissance? J. Urol. 179(1), 20-27 (2008).
44. Wang R, Wolf JS Jr, Wood DP Jr, Higgins EJ, Hafez KS. Accuracy of percutaneous core biopsy in management of small renal masses. Urology 73(3), 586-590, discussion 590-591 (2009).
45. Lechevallier E, Andre M, Barriol D et al. Fine-needle percutaneous biopsy of renal masses with helical CT guidance. Radiology 216(2), 506-510 (2000). (Pubitemid 30599874)
46. Leveridge M, Shiff D, Chung H et al. Small renal mass needle core biopsy: outcomes of non-diagnostic percutaneous biopsy and role of repeat biopsy (abstract 821). J. Urol. 183(4), E321 (2010).
47. Blumenfeld AJ, Guru K, Fuchs GJ, Kim HL. Percutaneous biopsy of renal cell carcinoma underestimates nuclear grade. Urology 76(3), 610-613 (2010).
48. Rothman J, Crispen PL, Wong YN, Al-Saleem T, Fox E, Uzzo RG. Pathologic concordance of sporadic synchronous bilateral renal masses. Urology 72(1), 138-142 (2008).
49. Pal SK, Kortylewski M, Yu H, Figlin RA. Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers. Mol. Cancer Ther. 9(12), 3115-3125 (2010).
50. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Functional imaging of renal cell carcinoma. Nat. Rev. Urol. 7(5), 258-266 (2010).
51. Lawrentschuk N, Scott AM, Davis ID. Potential of imaging biomarkers for characterization of renal masses. Expert Rev. Anticancer Ther. 10(6), 781-786 (2010).
52. Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124- labelled antibody chimeric G250 (124I cG250) and PET in patients with renal masses: a Phase I trial. Lancet Oncol. 8(4), 304-310 (2007). (Pubitemid 46464522)
53. Uzzo RG, Russo P, Chen D et al. The Multicenter Phase III REDECT Trial: a comparative study of 124 I-girentuximab- PET/CT versus diagnostic CT for the pre-operative diagnosis of clear cell renal cell carcinoma (ccRCC). Presented at: American Urologic Association Annual Meeting. San Francisco, CA, USA, 29 May-3 June 2010
54. Lane BR, Kattan MW. Prognostic models and algorithms in renal cell carcinoma. Urol. Clin. North. Am. 35(4) ,613-625; VII (2008).
55. Cindolo L, Patard JJ, Chiodini P et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104(7), 1362-1371 (2005). (Pubitemid 41356151)
56. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW. Preoperative nomogram predicting 12 year probability of metastatic renal cancer. J. Urol. 179(6), 2146-2151 (2008).
57. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58(2), 141-145 (2001). (Pubitemid 32728040)
58. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J. Urol. 182(3), 844-853 (2009).
59. Ficarra V, Novara G, Secco S et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. Eur. Urol. 56(5), 786-793 (2009).
60. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. J. Urol. 183(5), 1708-1713 (2010).
61. Kutikov A, Smaldone MC, Egleston BL et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur. Urol. 60(2), 241-248 (2011).
62. Smaldone MC, Kutikov A, Egleston BL et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer doi: 101002/cncr.26369 (2011) (Epub ahead of print).
63. Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115(13), 2844-2852 (2009).
64. Ozono S, Miyao N, Igarashi T et al. Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer. Jpn. J. Clin. Oncol. 34(2), 82-85 (2004). (Pubitemid 43115324)
65. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J. Urol. 175(2), 425-431 (2006). (Pubitemid 43067318)
66. Haramis G, Mues AC, Rosales JC et al. Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 77(4), 787-791 (2011).
67. Jewett MA, Mattar K, Basiuk J et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur. Urol. 60(1), 39-44 (2011).
68. Mason RJ, Abdolell M, Trottier G et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur. Urol. 59(5), 863-867 (2011).
69. Mues AC, Haramis G, Badani K et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology 76(3), 620-623 (2010).
70. Siu W, Hafez KS, Johnston WK 3rd, Wolf JS Jr. Growth rates of renal cell carcinoma and oncocytoma under surveillance are similar. Urol Oncol. 25(2), 115-119 (2007). (Pubitemid 46349757)
71. Neuzillet Y, Lechevallier E, Andre M, Daniel L, Nahon O, Coulange C. Follow-up of renal oncocytoma diagnosed by percutaneous tumor biopsy. Urology 66(6), 1181-1185 (2005). (Pubitemid 41797286)
72. Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG. Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 112(5), 1051-1057 (2008). (Pubitemid 351304589)
73. Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J. Urol. 177(3), 849-853, discussion 53-54 (2007).
74. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 197(3), 589-597 (1995).
75. Wehle MJ, Thiel DD, Petrou SP, Young PR, Frank I, Karsteadt N. Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 64(1), 49-52 (2004). (Pubitemid 38887577)
76. Letourneau I, Ouimet D, Dumont M, Pichette V, Leblanc M. Renal replacement in end-stage renal disease patients over 75 years old. Am. J. Nephrol. 23(2), 71-77 (2003). (Pubitemid 36164599)
77. Chang SL, Cipriano LE, Harshman LC, Garber AM, Chung BI. Cost-effectiveness analysis of nephron sparing options for the management of small renal masses. J. Urol. 185(5), 1591-1597 (2011).
78. Abouassaly R, Yang S, Finelli A, Kulkarni GS, Alibhai SM. What is the best treatment strategy for incidentally detected small renal masses? A decision analysis. BJU Int. doi: 101111/j.1464-410X.201110115x (2011) )Epub ahead of print).
79. Crispen PL, Uzzo RG. The natural history of untreated renal masses. BJU Int. 99(5 Pt B), 1203-1207 (2007). (Pubitemid 46624160)
80. Fujimoto N, Sugita A, Terasawa Y, Kato M. Observations on the growth rate of renal cell carcinoma. Int. J. Urol. 2(2), 71-76 (1995).
81. Oda T, Miyao N, Takahashi A, Yanase M et al. Growth rates of primary and metastatic lesions of renal cell carcinoma. Int. J. Urol. 8(9), 473-477 (2001). (Pubitemid 32953817)
82. Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer 100(4), 738-745 (2004). (Pubitemid 38176851)
83. Kato M, Suzuki T, Suzuki Y, Terasawa Y, Sasano H, Arai Y. Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J. Urol. 172(3), 863-866 (2004). (Pubitemid 39096408)
84. Sowery RD, Siemens DR. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can. J. Urol. 11(5), 2407-2410 (2004).
85. Lamb GW, Bromwich EJ, Vasey P, Aitchison M. Management of renal masses in patients medically unsuitable for nephrectomy-natural history, complications, and outcome. Urol. 64(5), 909-913 (2004). (Pubitemid 39469504)
86. Kouba E, Smith A, McRackan D, Wallen EM, Pruthi RS. Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J. Urol. 177(2), 466-470 (2007). (Pubitemid 46054008)
87. Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S. Active surveillance for selected patients with renal masses : updated results with long-term follow-up. Cancer 110(5), 1010-1014 (2007). (Pubitemid 47312866)
88. Fernando HS, Duvuru S, Hawkyard SJ. Conservative management of renal masses in the elderly: our experience. Int. Urol. Nephrol. 39(1), 203-207 (2007). (Pubitemid 46722967)
89. Matsuzaki M, Kawano Y, Morikawa H, Shiga Y, Murata H, Komatsu H. Conservative management of small renal tumors. Hinyokika Kiyo 53(4), 207-211 (2007).
90. Wong JA, Rendon RA. Progression to metastatic disease from a small renal cell carcinoma prospectively followed with an active surveillance protocol. Can. Urol. Assoc. J. 1(2), 120-122 (2007).
91. Abouassaly R, Lane BR, Novick AC. Active surveillance of renal masses in elderly patients. J. Urol. 180(2), 505-508 (2008).
92. Beisland C, Hjelle KM, Reisaeter LA, Bostad L. Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur. Urol. 55(6), 1419-1427 (2009).
93. Rosales JC, Haramis G, Moreno J et al. Active surveillance for renal cortical neoplasms. J. Urol. 183(5), 1698-1702 (2010).
94. Kassouf W, Aprikian AG, Laplante M, Tanguay S. Natural history of renal masses followed expectantly. J Urol. 171(1), 111-113 (2004). (Pubitemid 37549102)